Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. - Archive ouverte HAL Access content directly
Journal Articles Blood Year : 2006

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

, , , (1) , , , (2, 3) , (4) , (5, 6) , , (7) , , (8) , (9) , (10) , , , (11, 12) , , , (13) , (14) , (15) , (16) , (17) , , , (18)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Sylvain Choquet
  • Function : Author
Veronique Leblond
  • Function : Author
Raoul Herbrecht
Gérard Socié
Anne-Marie Stoppa
  • Function : Author
Peter Vandenberghe
  • Function : Author
Walter Feremans
  • Function : Author
Marie-Noelle Peraldi
  • Function : Author
Jeanne Luce Garnier
  • Function : Author
Thierry Lamy
  • Function : Author
Augustin Ferrant
  • Function : Author
Fritz Offner
  • Function : Author
Nathalie Berriot-Varoqueaux
  • Function : Author
Loïc Bergougnoux
  • Function : Author

Abstract

B-cell posttransplantation lymphoproliferative disorder (B-PTLD) is a rare but severe complication of transplantation, with no consensus on best treatment practice. This prospective trial, the first to test a treatment for PTLD, was designed to evaluate the efficacy and safety of rituximab in patients with B-PTLD after solid organ transplantation (SOT). Forty-six patients were included and 43 patients were analyzed. Patients were eligible if they had untreated B-PTLD that was not responding to tapering of immunosuppression. Treatment consisted of 4 weekly injections of rituximab at 375 mg/m2. At day (d) 80, 37 (86%) patients were alive, and the response rate was 44.2%, including 12 complete response/unconfirmed complete response (CR/CRu). The only factor predictive of a response at d80 was a normal lactate dehydrogenase level (P = .007, odds ratio [OR] = 6.9). At d360, responses were maintained in 68% of patients, and 56% of patients were alive. The overall survival rate at 1 year was 67%. We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments.
Not file

Dates and versions

hal-00452946 , version 1 (03-02-2010)

Identifiers

Cite

Sylvain Choquet, Veronique Leblond, Raoul Herbrecht, Gérard Socié, Anne-Marie Stoppa, et al.. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.. Blood, 2006, 107 (8), pp.3053-7. ⟨10.1182/blood-2005-01-0377⟩. ⟨hal-00452946⟩
211 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More